Menarini Group’s Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s breast cancer candidate in a deal potentially worth more than $500 million.
First AI-generated small molecule drug enters Phase II trial
Hong Kong-based artificial intelligence (AI)-powered drug discovery company Insilico Medicine has completed administering the first dose of its AI-discovered drug in a Phase II clinical trial.
Insilico Medicine has announced plans to commence clinical trials of its orally available 3CLpro inhibitor ISM3312 in China for the treatment of Covid-19 patients.
When we talk about Artificial Intelligence (AI) in drug discovery, it can still seem like a thing of the future, something the industry is still working towards. However, the AI-driven drug discovery company Insilico Medicine (Pak Shek Kok, Hong Kong) has firmly brought AI drug discovery into the present, with it’s recent US FDA approval for INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under an orphan designation.
SingHealth Duke-NUS Academic Medical Centre (AMC) in Singapore has announced a transformational gift of $50 million from the Lee Foundation that will support the advancement of innovation and research through programmes and initiatives in the AMC Health Discovery District – an ecosystem of innovation centres connecting each SingHealth campus, including the upcoming Eastern General Hospital.
Sanofi has once again entered into a partnership with an artificial intelligence-based drug development firm - this time with Insilico Medicine – in a deal that could be worth as much as $1.2 billion.
Days after topping up Insilico Medicine’s cash reserves with a $60 million round, the global AI player is redesigning its executive structure with an unusual twist as it shifts from pure drug design and discovery and builds out the pipeline with clinical stage assets.
US and Hong Kong-based startup Insilico Medicine has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.
The latest fundraising round, which follows a $255 million series C last year, was led by Warburg Pincus, B Capital Group and Qiming Venture Partners, among others. It comes at a critical juncture for Insilico: Its first AI-discovered med is now in the clinic, a major milestone as company leaders look to vet the quality of its technology. And the company is looking to rinse and repeat this process for the more than two dozen wholly owned assets in its pipeline.